Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

Key Points

Question  What is the cost-effectiveness of the proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab in patients with atherosclerotic cardiovascular disease?

Findings  In this study, a Markov cohort state-transition model determined that adding evolocumab at current list price to patients receiving standard background therapy was estimated to cost $268 637 per quality-adjusted life-year gained. Sensitivity and scenario analyses demonstrated incremental cost-effectiveness ratios ranging from $100 193 to $488 642 per quality-adjusted life-year.

Meaning  To achieve a threshold of $150 000 per quality-adjusted life-year gained in patients with atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 70 mg/dL and an annual event rate of 6.4 per 100 patient-years, an annual net price of $9669 or a higher risk population would need to be treated.

Importance  The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab has been demonstrated to reduce the composite of myocardial infarction, stroke, or cardiovascular death in patients with established atherosclerotic cardiovascular disease. To our knowledge, long-term cost-effectiveness of this therapy has not been evaluated using clinical trial efficacy data.

Objective  To evaluate the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background therapy.

Design, Setting, and Participants  A Markov cohort state-transition model was used, integrating US population-specific demographics, risk factors, background therapy, and event rates along with trial-based event risk reduction. Costs, including price of drug, utilities, and transitional probabilities, were included from published sources.

Exposures  Addition of evolocumab to standard background therapy including statins.

Main Outcomes and Measures  Cardiovascular events including myocardial infarction, ischemic stroke and cardiovascular death, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), and net value-based price.

Results  In the base case, using US clinical practice patients with atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 70 mg/dL (to convert to millimoles per liter, multiply by 0.0259) and an annual events rate of 6.4 per 100 patient-years, evolocumab was associated with increased cost and improved QALY: incremental cost, $105 398; incremental QALY, 0.39, with an ICER of $268 637 per QALY gained ($165 689 with discounted price of $10 311 based on mean rebate of 29% for branded pharmaceuticals). Sensitivity and scenario analyses demonstrated ICERs ranging from $100 193 to $488 642 per QALY, with ICER of $413 579 per QALY for trial patient characteristics and event rate of 4.2 per 100 patient-years ($270 192 with discounted price of $10 311) and $483 800 if no cardiovascular mortality reduction emerges. Evolocumab treatment exceeded $150 000 per QALY in most scenarios but would meet this threshold at an annual net price of $9669 ($6780 for the trial participants) or with the discounted net price of $10 311 in patients with low-density lipoprotein cholesterol levels of at least 80 mg/dL.

Conclusions and Relevance  At its current list price of $14 523, the addition of evolocumab to standard background therapy in patients with atherosclerotic cardiovascular disease exceeds generally accepted cost-effectiveness thresholds. To achieve an ICER of $150 000 per QALY, the annual net price would need to be substantially lower ($9669 for US clinical practice and $6780 for trial participants), or a higher-risk population would need to be treated.

Despite major advances in the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), substantial risk of recurrent cardiac events, stroke events, and cardiovascular death remains as well as high disease burden affecting quality of life and costs.^1-7 Lowering low-density lipoprotein (LDL) cholesterol levels with certain therapies, including statins, reduces cardiovascular events.^8,9 Yet, many patients with established ASCVD need further LDL cholesterol lowering and remain at substantial risk for cardiovascular events despite optimal statin therapy.^1,4,9 In the past 5 years, monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have demonstrated marked LDL cholesterol level lowering. Evolocumab, a fully human monoclonal antibody against PCSK9, lowers LDL cholesterol by approximately 60%.^10-13 The evolocumab cardiovascular outcomes trial, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER),¹⁴ demonstrated that the addition of evolocumab to standard background therapy, including moderate- to high-intensity statin therapy, reduced incidence of cardiovascular events in patients with established ASCVD.

Cost-effectiveness of new therapies is important as health care costs rise, and accurate information about value and potential tradeoffs among therapies is essential. Several analyses have assessed the potential economic value of PCSK9 inhibitors in patient populations with varied risk levels,^7,15-18 extrapolating cardiovascular event reduction rate ratios per 38.67 mg/dL of LDL cholesterol reduction observed in the Cholesterol Treatment Trialists Collaboration (CTTC) meta-analyses of statin trials (to convert LDL cholesterol to millimoles per liter, multiply by 0.0259).^8,19,20 To our knowledge, the FOURIER results provide the first opportunity to assess cost-effectiveness of evolocumab for the reduction of subsequent cardiovascular events in an ASCVD population using specific PCSK9 inhibition trial-based efficacy data.

In this study, a Markov cohort state-transition model was used to assess the cost-effectiveness of evolocumab when added to standard background therapy in clinical practice patients with established ASCVD from a societal and US health plan perspective to help better identify the patient populations and value-based price where the use of evolocumab treatment would provide value.

A Markov cohort state-transition model was used, considering the US societal perspective and assuming lifetime horizon to capture the lifetime progression of ASCVD in adults. A similar model to that used previously to estimate cost-effectiveness and value-based price range of evolocumab using LDL cholesterol–lowering data from the statin trials and cardiovascular event reduction from CTTC meta-analyses^7,17 was used. The model (eFigure 1 in the Supplement) was used to predict subsequent cardiovascular events and cardiovascular- or noncardiovascular-related mortality as a function of age, sex, LDL cholesterol level, and cardiovascular event history. The model transition-states were adapted to match those analyzed in FOURIER.¹⁴ The model comprises mutually exclusive health states that include ASCVD, 2 acute event states (myocardial infarction and ischemic stroke for a 1-year duration), and postevent health states and their combination that are introduced to enable the model to account for event recurrence. In addition, distinctions are made between cardiovascular and noncardiovascular death. Revascularization is included as a procedure and not as a separate health state because it is assumed that it does not affect cardiovascular event risk or quality of life.

A representative clinical practice-based population with established ASCVD was modeled to embody the US patient population. Patients were selected from the US population–weighted National Health and Nutrition Examination Surveys based on individuals 18 years or older (mean age, 66 years) with a recorded atherosclerotic cardiovascular condition and LDL cholesterol level of at least 70 mg/dL (mean, 104 mg/dL) while receiving statin therapy (Table 1). Written informed consent was obtained from National Health and Nutrition Examination Survey participants. The survey was approved by the National Center for Health Statistics ethics review board.

The Truven MarketScan database, a large-scale database of claims for commercially insured patients and patients with Medicare Supplemental insurance, was used to estimate contemporary cardiovascular event rates for US patients with ASCVD.¹⁵ However, cardiovascular-related death data were not complete in MarketScan. Cardiovascular mortality rates were estimated by combining multiple National Health and Nutrition Examination Surveys death files (2004-2012) and National Vital Statistics Report 2012.¹⁵ Rates were adjusted by baseline LDL cholesterol levels and age and previous event history.²¹ Ten-year and lifetime event rates for this population are shown in eTable 1 in the Supplement. These rates reflect multiple events. For reference, the annual cardiovascular event rate (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) was 6.4 per 100 patient-years in this US practice-based population, whereas in participants in the FOURIER trial placebo plus standard background therapy arm, the event rate (including multiple events) was 4.2 per 100 patient-years (eTable 2 in the Supplement).¹⁴ The noncardiovascular mortality rate was assumed to be that of the general US population.²²

Hazard ratios were based on landmark analysis of the individual end points in FOURIER of nonfatal myocardial infarction, nonfatal ischemic stroke, and coronary revascularization, with respective risk reductions of 21%, 26%, and 16% in the first year and 36%, 25%, and 28% beyond year 1 (Table 2), as previously published.¹⁴ Cardiovascular event rate ratios per 38.67 mg/dL of LDL cholesterol reduction were derived from the hazard ratios and the LDL cholesterol reduction reported in the trial (53.36 mg/dL) and then applied in the model (Table 2). In FOURIER, cardiovascular mortality reduction was not observed within the first 3 years of follow-up. In the base case, risk reduction for cardiovascular mortality was set at 0% for the first 5 years and then estimated to proportionally match the cardiovascular mortality event reduction in the CTTC meta-analysis⁸ for overall or more vs less intensive statin therapy when appropriate thereafter (risk reduction 9.5% per 38.67 mg/dL LDL cholesterol reduction) (eTable 3 in the Supplement). The 5-year delay before the emergence of cardiovascular mortality reduction was selected in the base case to be consistent with findings from contemporary greater-intensity LDL cholesterol–lowering clinical outcome trials in which cardiovascular mortality reduction was not observed in the first 5 years.^9,27,28 Consistent with the safety profile reported in FOURIER, among patients receiving evolocumab, 2.1% were assumed to develop mild injection site reactions over 2 years, resulting in a small quality-of-life decrement (Table 2). Evolocumab therapy persistence rates over time were based on those observed in FOURIER during the first 3 years of follow-up and then kept steady. Within-trial persistence and adherence effects on efficacy were already reflected in the intention-to-treat hazard ratios reported in FOURIER during the first 3 years and modeled as not further varying.

Direct medical costs associated with cardiovascular events were obtained through US claims data^23,24 and adjusted for inflation to January 2017 using the Consumer Price Index.²⁹ Indirect cost estimates were obtained from the 2017 American Heart Association/American Stroke Association report on cardiovascular disease burden by applying reported ratios of direct and indirect costs.²⁵ Noncardiovascular death events were assumed to incur no costs and not vary by treatment allocation. Medication cost of evolocumab in the base case was based on the current wholesale acquisition cost for evolocumab, $14 523 (list price). Additional analyses were performed based on the estimated mean annual net cost of $10 311 (list price minus an average rebate of 29% for branded pharmaceuticals).³⁰ The average of Red Book prices and the market share of generic simvastatin and atorvastatin were used for standard therapy ($68) and ezetimibe ($2780).³¹ Additional analyses used ezetimibe priced similarly to generic statin therapy ($68). Utility estimates for cardiovascular health states were based on results of a time tradeoff study.²⁶

The lifetime cost and quality-adjusted life-years (QALY) accrued under the 2 treatment options, evolocumab added to standard background therapy (moderate- to high-intensity statin with or without ezetimibe) vs standard background therapy alone, were projected through simulation. The incremental cost-effectiveness ratio (ICER) was calculated as the incremental cost per QALY gained. The analysis considered a cost-effectiveness threshold of $150 000 per QALY gained in the base case, aligned with the American College of Cardiology/American Heart Association statement on cost/value methods for intermediate vs low value,³² recommendations from the World Health Organization,³³ and contemporary literature.³⁴ The annual net value–based price to achieve an ICER of $150 000 per QALY gained was calculated. A range of willingness-to-pay thresholds were also considered.^34,35 Additional model outcomes included the probabilistic mean and 95% credible intervals for the net value–based price. The QALY and costs were discounted at an annual rate of 3.0%, consistent with the Second US Panel on Cost-effectiveness in Health and Medicine recommendation.³⁵

Sensitivity analyses were conducted to reflect uncertainty in model inputs and to assess robustness of model outcomes. In the deterministic sensitivity analyses, model parameter values (Table 2) were varied individually through plausible ranges (eg, 95% confidence intervals). Probabilistic sensitivity analyses examined the combined effect of parameter uncertainty on the model results. A sensitivity analysis was performed using the FOURIER patient population characteristics and cardiovascular event rates analyses. We also analyzed in the clinical practice population analyses where the background cardiovascular event rates were 25% and 50% higher or lower of those in US clinical practice. As a sensitivity analysis, a range of cardiovascular mortality effect sizes were applied to assess the effect on overall results (eTable 3 in the Supplement). Additional sensitivity analyses included extreme cases where all hazard ratios were increased or decreased simultaneously by 1 SE.

A range of scenario analyses were considered including modeling a 3-year, 7-year, or infinite delay of treatment effect on cardiovascular mortality; modeling treatment effect on myocardial infarction, stroke, and cardiovascular mortality based on the corresponding key secondary end point from FOURIER; and modeling cost-effectiveness confined to patients with ASCVD with baseline LDL cholesterol levels of at least 100 mg/dL (mean, 130 mg/dL). A scenario analysis was performed where the risk ratios derived from the FOURIER key secondary end point did not vary from year 1 and subsequent years. In addition, scenario analyses with ezetimibe priced similarly to generic statin therapy ($68), where all patients with ASCVD were treated with ezetimibe and statin therapy and where only the US payer perspective was considered (no indirect costs) were performed. We also analyzed what LDL cholesterol treatment initiation threshold for the population would yield an ICER of $150 000 per QALY gained at current list price and current net drug price (value-based LDL-cholesterol treatment initiation threshold). Furthermore, we determined the annual event rate thresholds where the current list price and net price of evolocumab would yield an ICER of $150 000.

The model was developed using Microsoft Excel 2013, version 14.0 (Microsoft). The Impact Inventory Template and the Reporting Checklist for Cost-effectiveness Analyses from the Second Panel on Cost-effectiveness in Health and Medicine³⁵ are in eTables 4 and 5 in the Supplement.

In the base case using a US clinical practice patient population, the LDL cholesterol level was at least 70 mg/dL (mean, 104 mg/dL) and the cardiovascular event rate was 6.4 per 100 patient-years with standard background therapy. In this base case, mean lifetime costs would be $234 877 per patient treated with standard therapy and $340 275 per patient treated with evolocumab added to standard background therapy, with incremental costs of $105 398 (Table 3; eTable 6 in the Supplement). The lifetime QALY was 7.23 with standard background therapy and 7.62 with evolocumab, with a difference in health effects of 0.39 QALY. Compared with standard background therapy alone, use of evolocumab at its current list price ($14 523) results in an ICER of $268 637 per QALY gained (Table 3). If, instead, a net price of evolocumab reflecting a 29% discount was used ($10 311), the ICER would be $165 689 per QALY. To achieve a value threshold of $150 000 per QALY gained, a value-based net price of $9669 annually would be required (Table 3). The net value-based prices at ICERs of $50 000, $100 000, $150 000, $200 000, and $250 000 per QALY would be $5578, $7623, $9669, $11 715, and $13 760 per year, respectively. For the FOURIER trial participants, the ICER would be $413 579 per QALY, and the net value-based price would be $6780 (Table 3). Net value-based prices at ICERs of $50 000, $100 000, $150 000, $200 000, and $250 000 per QALY would be $3843, $5312, $6780, $8249, and $9718 per year, respectively.

When we varied the background cardiovascular event rates for the US clinical practice population by 25% and 50% higher or lower, the ICER ranged from $194 551 to $488 642 per QALY, and the net value-based price ranged from $12 218 to $6164 (Table 4 and Figure). Testing the treatment benefit for cardiovascular mortality beginning after 5 years of follow-up across risk reductions ranging from 14.0% to 6.4% per 38.67 mg/dL LDL cholesterol yielded an ICER range from $225 575 to $313 163 per QALY and a net value-based price range from $10 773 to $8872 (Table 4). Deterministic sensitivity analyses are presented in eFigure 2 in the Supplement. Probabilistic sensitivity analyses at list price revealed a mean ICER of $275 124 per QALY and a mean net value-based price of $9565, with 95% of values between $6313 and $12 418. The probabilistic mean and 95% credible intervals of the net value-based prices are shown in eFigure 3 in the Supplement.

We tested various assumptions of the treatment benefit (Table 4). A 3-year time before cardiovascular mortality benefits emerge yielded an ICER of $245 066 and a value-based net price of $10 221 per year. A 7-year delay in the cardiovascular mortality treatment benefit yielded an ICER of $293 720 per QALY, and a net value-based price of $9188 per year. In the case of no lifetime cardiovascular mortality reduction, the ICER was $483 800 per QALY, and the net value-based price was $7246. This reflects the improvements in the rate of subsequent events, health state utilities (the quality of the life-years), and cardiovascular disease events and procedures costs by reducing nonfatal events, even in the absence of direct survival benefit. Additional scenarios are shown in Table 4. If all patients were receiving ezetimibe and statin therapy, then the ICER was $271 313. When only the US payer perspective was integrated into the model, then the ICER was $304 392 per QALY, and the net value-based price was $8206. At current list price, the LDL cholesterol treatment initiation threshold for patients with ASCVD that would yield an ICER of $150 000 per QALY was calculated to be at least 119 mg/dL (at this threshold, mean LDL cholesterol level for the ASCVD population is 144 mg/dL) and at the discounted price at least 80 mg/dL (at this threshold, mean LDL cholesterol level for the ASCVD population is 110 mg/dL). The annual event rate for the ASCVD population that would yield an ICER of $150 000 per QALY was calculated to be 13.5 per 100 patient-years at list price and 7.1 per 100 patient-years at the discounted price.

In this study, a model based on the clinical risk reduction demonstrated in FOURIER and extrapolated over lifetime was used to investigate the economic value of evolocumab in a US clinical practice–based population of patients with established ASCVD. This evaluation has found that evolocumab at its current list price of $14 523, when added to standard background therapy, including statins, in patients with established ASCVD with a background event rate of 6.4 per 100 patient-years had an ICER of $268 637. This ICER exceeds the threshold established by the World Health Organization for cost-effectiveness and the American College of Cardiology/American Heart Association threshold for intermediate vs low value.^32,33 The ICER would be substantially higher if cardiovascular mortality benefits with evolocumab were not to emerge or if the cardiovascular event rates were similar to those in FOURIER. Evolocumab therapy could meet the threshold of $150 000 per QALY with an annual value-based price of $9669 for a population with an event rate of 6.4 per 100 patient-years. This evaluation provides insights as to the economic implications of evolocumab therapy if applied to eligible patients with ASCVD in US clinical practice.

Sensitivity and scenario analyses resulted in ICERs that, with few exceptions, exceeded the American College of Cardiology/American Heart Association intermediate value and World Health Organization cost-effectiveness thresholds. However, a value-based net annual price of $9669 would yield an ICER of $150 000 per QALY in an ASCVD clinical practice population.^32,33 The treatment effect on cardiovascular mortality in the base case is supported by data from mendelian randomization analyses demonstrating virtually identical lower odds of coronary heart disease mortality in patients with lifelong genetically mediated lower LDL cholesterol levels either from variants in 3-hydroxy-3-methylglutaryl-coenzyme A reductase or in PCSK9.³⁶ In the scenario that no cardiovascular mortality benefit was to emerge, the ICER would be $483 800 per QALY gained, substantially exceeding current intermediate value and cost-effectiveness thresholds. The base case reflects the characteristics and event rates of patients with ASCVD in US clinical practice. If the characteristics and event rates are similar to those in FOURIER, treatment with evolocumab would lead to an ICER of $413 579 and a value-based net annual price of $6780.

Despite significantly higher medication costs, the incremental reduction in cardiovascular events, corresponding reductions in hospitalizations, and revascularizations resulting from the addition of evolocumab therapy drives the ICER. In patients with established ASCVD who, with other currently available lipid-modifying therapies including maximally tolerated statins, require additional LDL cholesterol lowering, adding evolocumab could facilitate improved clinical outcomes for a considerable proportion of patients.^15,16 Substantial population health improvements and further progress toward reduction in noncommunicable diseases could result.¹⁵ However, with an ICER of $268 637 per QALY with the current list price, there are legitimate concerns regarding the appropriate allocation of health care resources along with challenges in coverage and access to this therapy, despite demonstration of clinical event reduction in FOURIER. Adopting a net value-based price of $9669 annually would be 1 potential strategy that could affect the value proposition and willingness to pay. Targeting a subset of patients with ASCVD who are at particularly high risk for events based on clinical factors, formal risk scores, or use of a higher LDL cholesterol treatment initiation threshold for the addition of evolocumab therapy would be alternative approaches to improve value and limit expenditures.¹⁶ At an LDL cholesterol treatment initiation threshold of at least 100 mg/dL, evolocumab therapy would be cost-effective with an ICER of $100 193 per QALY for a US clinical practice ASCVD population, with an event rate of 6.4 per 100 patient-years, but only at a net price of $10 311.

This study provides, to our knowledge, the first cost-effectiveness data on evolocumab integrating the results of FOURIER. Prior cost-effectiveness analyses of PCSK9 inhibition have been published based on the projected benefits of LDL cholesterol lowering on clinical events, with variable findings.^15-17 A prior analysis using a similar model from a US payer perspective suggested therapy at list price was cost-effective for patients with established ASCVD and LDL cholesterol levels of 100 mg/dL or higher.¹⁷ In contrast, a study using the Coronary Heart Disease Policy model from a US payer/health system perspective concluded that PCSK9 inhibition was not cost-effective.¹⁶ Several methodological differences may account for the discrepancies in these prior modeling studies and the Coronary Heart Disease Policy model may underestimate event risk overall.^37,38 The policy model did not consider indirect costs.

This study has several limitations. The results should be interpreted within the context of the data inputs and modeling assumptions used. Clinical outcomes data from FOURIER were limited to a median follow-up of 26 months, yet model predictions are based on the assumption that clinical benefits extend beyond the period with direct follow-up. If the clinical benefits differ from those modeled in this study, particularly in regards to the magnitude and timing of cardiovascular mortality reductions, the cost-effectiveness findings could be affected by overestimating or underestimating the cost-effectiveness of evolocumab therapy. Cost-effectiveness estimates could also be altered if significant adverse events materialize beyond 3 to 4 years of observation to date.³⁹ If the levels of persistence with and adherence to evolocumab therapy differ from those in FOURIER, costs and clinical effectiveness may be affected. This economic evaluation included indirect costs to apply the US societal perspective, as is preferred,³² but detailed data on indirect costs for each conditional state are limited. This analysis is only applicable to US patients with established ASCVD and is not generalizable to primary prevention patients, other populations at lower cardiovascular event risk, or patients outside the United States.

At its current list price of $14 523, the addition of evolocumab to standard background therapy in patients with ASCVD provides a treatment option that exceeds generally accepted cost-effectiveness thresholds. To achieve an ICER of $150 000 per QALY gained in a US clinical practice ASCVD population with an annual event rate of 6.4 per 100 patient-years, a price reduction with a net annual price of $9669 or with an annual net price of $10 311 targeting treatment in patients with LDL cholesterol levels of 80 mg/dL or higher would be needed. For the FOURIER trial participants, with an annual event rate of 4.2 per 100 patient-years, a net annual price of $6780 would be necessary. These findings highlight the need for a comprehensive disease management approach for ASCVD that includes vigorous lifestyle changes, assiduous adherence to all guideline-directed therapies, and judicious use of new, more costly therapies.

Corresponding Author: Gregg C. Fonarow, MD, Division of Cardiology, Ronald Reagan University of California, Los Angeles Medical Center, 10833 LeConte Ave, Room A2-237 CHS, Los Angeles, CA 90095-1679 (gfonarow@mednet.ucla.edu).

Accepted for Publication: June 24, 2017.

Published Online: August 23, 2017. doi:10.1001/jamacardio.2017.2762

Open Access: This article is published under the JN-OA license and is free to read on the day of publication.

Correction: This article was corrected on October 18, 2017, to correct an error in the y-axis of panel C of the Figure. The y-axis should read “VBP, $.”

Author Contributions: Drs Fonarow and Villa had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Fonarow, Keech, Pedersen, Lindgren, van Hout, Villa, Qian, Somaratne, Sabatine.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Fonarow, Keech, Villa.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Keech, van Hout, Villa, Qian.

Obtained funding: Fonarow, Qian, Somaratne.

Administrative, technical, or material support: Fonarow, Qian, Somaratne.

Supervision: Fonarow, Keech, Pedersen, van Hout, Qian, Somaratne, Sabatine.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Fonarow reports consulting for Amgen, Janssen, and Novartis. Dr Keech reports grants and personal fees from Abbott, Amgen, AstraZeneca, and Pfizer; grants and personal fees from Mylan and Sanofi; and is the recipient of a National Health and Medical Research Council of Australia Senior Principal Research Fellowship award. Dr Pedersen reports research grant support through his institution from Amgen and honoraria from Amgen, Boehringer Ingelheim, the Medicines Company, Merck, and Sanofi. Dr Giugliano reports research grant support through Brigham and Women’s Hospital from Amgen, Daiichi-Sankyo, and Merck, and honoraria from Amgen, Angel Med, Beckman-Coulter, Boehringer-Ingelheim, Bristol-MyersSquibb, CVS Caremark, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Lexicon, Merck, Portola, Pfizer, Regeneron, Sanofi, St Jude, and Stealth Peptides. Dr Sever reports research grant support through Imperial College from Amgen and is a recipient of an NIHR Senior Investigator Award and receives support from the Biomedical Research Centre Award to Imperial College Healthcare National Health Services Trust. Drs Lindgren and van Hout report consulting for Amgen. Dr Villa is an employee of Amgen (Europe), and Drs Qian and Somaratne are employees and stockholders of Amgen Inc. Dr Sabatine reports research grant support through Brigham and Women’s Hospital from Abbott Laboratories, Amgen, AstraZeneca, Critical Diagnostics, Daiichi-Sankyo, Eisai, Genzyme, Gilead, GlaxoSmithKline, Intarcia, Janssen Research Development, MedImmune, Merck, Novartis, Poxel, Roche Diagnostics, and Takeda and honoraria from Alnylam, Amgen, AstraZeneca, Cubist, CVS Caremark, Esperion, Intarcia, Ionis, Janssen Research and Development, Medicines Company, MedImmune, Merck, MyoKardia, and Zeus Scientific. No other disclosures were reported.

Funding/Support: This study was sponsored by Amgen Inc.

Role of the Funder/Sponsor: The sponsor provided funding for the study and via employee coauthors, under the direction of the FOURIER executive committee, provided input into the design and conduct of the study and collection, management, and analysis of the data review. The sponsor reviewed the manuscript prior to submission but the preparation, approval, and decision to submit the manuscript for publication were made by the coauthors.

Disclaimer: Drs Fonarow and Sabatine are Associate Editor and Deputy Editor, respectively, of JAMA Cardiology, but neither were involved in any of the decisions regarding review of the manuscript or its acceptance.

Additional Contributions: We thank Meera Kodukulla, PhD, Amgen Inc, for editorial support. She received compensation as an employee of Amgen Inc.